https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Clinical utility of a standardized chronic hypersensitivity pneumonitis exposure questionnaire https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52464 Wed 28 Feb 2024 15:57:57 AEDT ]]> Use of biologics to treat acute exacerbations and manage disease in asthma, COPD and IPF https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34285 Wed 06 Apr 2022 13:57:14 AEST ]]> Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43133 Tue 13 Sep 2022 15:14:32 AEST ]]> Bronchoconstriction and airway biology: potential impact and therapeutic opportunities https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28008 Sat 24 Mar 2018 07:27:19 AEDT ]]> Predicting Pulmonary Function From the Analysis of Voice: A Machine Learning Approach https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44823 Mon 24 Oct 2022 09:45:54 AEDT ]]> Plasma cell but not CD20-mediated B cell depletion protects from bleomycin-induced lung fibrosis. https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47318 + CD138⁺ plasma cells (PCs). Interestingly, high levels of CD138⁺ cells were also identified in the lung tissue of patients with IPF, consistent with the mouse model. Treatment of mice with bortezomib, which depletes PCs, reduced the level of Blm-induced lung fibrosis, implicating PCs as important effector cells in the development and progression of pulmonary fibrosis.]]> Fri 13 Jan 2023 11:00:15 AEDT ]]>